IP Library Granted Patent US 8,383,148
Granted Patent B2
US 8,383,148 · App. 13/526,431 · Granted Feb 26, 2013

Clay-based hemostatic agents and devices for the delivery thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,148
App. No.
13/526,431
Granted
Feb 26, 2013
Kind
B2
Abstract

A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate. Another device is a bandage comprising a substrate, a mesh mounted on the substrate, and particles of a clay material retained in the mesh. A hemostatic sponge comprises a substrate, a hemostatic material disposed on a first surface of the substrate, and a release agent disposed on a second surface of the substrate. The release agent is disposed on the wound-contacting surface of the substrate. When treating a bleeding wound, application of the hemostatic sponge causes at least a portion of the hemostatic material to come into contact with blood through the release agent and through the substrate.

Claims (43)

1. A method of manufacturing a hemostatic device comprising:

providing a clay material and a binder;

providing a gauze substrate comprising strands, the gauze strands initially existing separately from the clay material before the gauze strands and the clay material are combined;

applying the clay material and the binder to the substrate;

subjecting the substrate to a drying process after applying the clay material and the binder to the substrate;

wherein the binder has an effect of substantially preventing the separation of the clay material from the substrate before use; and

wherein the device is configured such that when treating bleeding, application of the device is capable of causing blood to be absorbed into the gauze and causing at least a portion of the clay material to come into direct contact with blood to assist in accelerating clotting.

2. The method of claim 1 , wherein the binder is a polyol.

3. The method of claim 1 , wherein the binder is selected from the group consisting of chitosan, cellulose, calcium alginate, and polyvinyl alcohol.

4. The method of claim 1 , wherein the clay material and binder are applied on at least two sides of the substrate.

5. The method of claim 1 , wherein the substrate is immersed in a slurry comprising the clay material and binder.

6. The method of claim 1 , wherein the substrate is sprayed with a slurry comprising the clay material and the binder.

7. The hemostatic device of claim 1 , wherein a slurry of the clay material and the binder is applied to the substrate using a slot-die technique.

8. The method of claim 1 , wherein the clay material comprises kaolin or kaolinite.

9. The method of claim 1 , wherein said clay material is selected from the group consisting of attapulgite, bentonite, kaolin, kaolinite, and combinations of the foregoing materials.

10. The method of claim 1 , further comprising applying to the substrate a pharmaceutically-active composition selected from the group consisting of antibiotics, antifungal agents, antimicrobial agents, anti-inflammatory agents, analgesics, antihistamines, compounds containing silver or copper ions, and combinations of the foregoing compositions.

11. The method of claim 1 , wherein the gauze substrate is fabricated from a material selected from the group consisting of cotton, silk, wool, plastic, cellulose, rayon, polyester, and combinations of the foregoing.

12. The method of claim 1 , wherein the gauze substrate is flexible to allow the gauze substrate to form to a shape of a bleeding wound and to retain the shape of the bleeding wound.

13. The method of claim 1 , further comprising applying a release agent to the substrate.

14. The method of claim 13 , wherein said release agent is selected from the group consisting of polyvinyl alcohol, silicone, carboxymethyl cellulose, and gelatinized starch.

15. The method of claim 8 , wherein the kaolin or kaolinite comprises particles having diameters of about 0.2 mm.

16. A method of using a hemostatic device to accelerate the clotting of blood from a wound comprising:

obtaining a sterile hemostatic device comprising

a gauze substrate comprising strands,

a clay material and a binder applied to the gauze,

wherein the gauze strands initially exist separately from the clay material before the clay material is applied to the gauze strands,

wherein the binder has an effect of substantially suppressing clay dust, and

wherein the device is configured such that the device is capable of causing blood to be absorbed into the substrate; and

applying the gauze directly to a surface of a bleeding wound to allow the clay material to come into direct contact with blood from the wound to stop bleeding.

17. The method of claim 16 , wherein the binder is a polyol.

18. The method of claim 16 , wherein the binder is selected from the group consisting of chitosan, cellulose, calcium alginate, and polyvinyl alcohol.

19. The method of claim 16 , wherein the clay material and binder are disposed on at least two sides of the substrate.

20. The method of claim 16 , wherein the clay material and binder are applied to the substrate by immersing the substrate in a slurry of the clay material and the binder.

21. The method of claim 16 , wherein the clay material and binder are applied to the substrate by spraying a slurry of the clay material and the binder onto at least one surface of the substrate.

22. The method of claim 16 , wherein the clay material and binder are applied to the substrate by a slot-die technique.

23. The method of claim 16 , wherein the clay material comprises kaolin or kaolinite.

24. The method of claim 16 , wherein said clay material is selected from the group consisting of attapulgite, bentonite, kaolin, kaolinite, and combinations of the foregoing materials.

25. The method of claim 16 , further comprising applying to the substrate a pharmaceutically-active composition selected from the group consisting of antibiotics, antifungal agents, antimicrobial agents, anti-inflammatory agents, analgesics, antihistamines, compounds containing silver or copper ions, and combinations of the foregoing compositions.

26. The method of claim 16 , wherein the gauze substrate is fabricated from a material selected from the group consisting of cotton, silk, wool, plastic, cellulose, rayon, polyester, and combinations of the foregoing.

27. The method of claim 16 , wherein the gauze substrate is flexible to allow the gauze substrate to form to a shape of a bleeding wound and to retain the shape of the bleeding wound.

28. The method of claim 16 , further comprising applying a release agent to the substrate.

29. The method of claim 28 , wherein said release agent is selected from the group consisting of polyvinyl alcohol, silicone, carboxymethyl cellulose, and gelatinized starch.

30. The method of claim 23 , wherein the kaolin or kaolinite comprises particles having diameters of about 0.2 mm.

Assignments (18)
SECURITY INTEREST Recorded Mar 1, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 066723/0376 →
CHANGE OF NAME Recorded Feb 29, 2024
From: TELEFLEX TECHNOLOGIES LLC
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066836/0737 →
MERGER Recorded Feb 29, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: TELEFLEX TECHNOLOGIES LLC
Reel/Frame 066707/0695 →
MERGER Recorded Feb 16, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: TELEFLEX TECHNOLOGIES LLC
Reel/Frame 066621/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: TELEFLEX LIFE SCIENCES LIMITED
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066616/0701 →
CHANGE OF NAME Recorded Feb 16, 2024
From: TELEFLEX TECHNOLOGIES LLC
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066621/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: TELEFLEX LIFE SCIENCES LIMITED
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066434/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: Z-MEDICA, LLC
To: TELEFLEX LIFE SCIENCES LIMITED
Reel/Frame 058740/0387 →
SECURITY INTEREST Recorded Mar 2, 2021
From: Z-MEDICA, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 055455/0099 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2021
From: TWIN BROOK CAPITAL PARTNERS, LLC
To: Z-MEDICA, LLC
Reel/Frame 054832/0770 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INADVERTENT OMISSION OF APPLICATION NO. 14/185873 FROM THE COVER SHEET PREVIOUSLY RECORDED AT REEL: 044151 FRAME: 0282. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 22, 2020
From: MADISON CAPITAL FUNDING LLC
To: Z-MEDICA, LLC
Reel/Frame 054882/0904 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 035308/0704 Recorded Oct 9, 2017
From: MADISON CAPITAL FUNDING LLC
To: Z-MEDICA, LLC
Reel/Frame 044151/0282 →
SECURITY INTEREST Recorded Sep 29, 2017
From: Z-MEDICA, LLC
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 043738/0690 →
RELEASE AND REASSIGNMENT Recorded Apr 9, 2015
From: ABACUS FINANCE GROUP, LLC
To: Z-MEDICA, LLC
Reel/Frame 035389/0800 →
SECURITY INTEREST Recorded Apr 1, 2015
From: Z-MEDICA, LLC
To: MADISON CAPITAL FUNDING LLC, AS AGENT
Reel/Frame 035308/0704 →
MERGER Recorded Apr 1, 2015
From: Z-MEDICA CORPORATION
To: Z-MEDICA, LLC
Reel/Frame 035353/0423 →
SECURITY AGREEMENT Recorded Sep 6, 2012
From: Z-MEDICA, LLC
To: ABACUS FINANCE GROUP, LLC
Reel/Frame 028917/0898 →
MERGER Recorded Sep 4, 2012
From: Z-MEDICA CORPORATION
To: Z-MEDICA, LLC
Reel/Frame 028896/0108 →